Genprex (GNPX) is a Small Cap Company in the Genetics Sector Working with Big Pharma and Generating Big Potential
“Groundbreaking, potentially curative gene therapy shown to transform alpha cells in the pancreas into functional beta-like cells is potentially applicable to both Type 1 and Type 2 diabetes”
Good day everyone,
We are updating our coverage of Genprex, Inc. (NASDAQ: GNPX), a clinical stage gene therapy company involved in developing various approaches to treating cancer and diabetes.
Current price $3.79 per share
Outstanding shares (est.) 43.2M
Shares in Float (est.) 33.7M
Insider ownership 17.4%
Institutional ownership 18.6%
We last issued a report on GNPX December 21st of 2020. At that time, the company shares were at $3.50 and gained 41% over two days. By February 8th, 2021 GNPX shares reached a high of $7.72/share. With the current share price, and new developments at the company we believe similar movements in the share price could come near term.
The company stock chart indicates that GNPX shares have fallen below their 50 DMA and 200 DMA of $4.55 and $4.07, respectively. The current RSI (14) is 40.56. These data can be indicators of oversold shares. The company’s stock performance this year, and the absence any adverse events, may indicate the potential for a large near-term gain.
Since February, the company shares have consolidated, and we want to note that according to shortsqueeze.com there are 4.17M GNPX shares shorted or 12.3% of the public float.
The leading-edge technology offered by GNPX, in the field of genetics, is being watched by many in the biopharma sector, not only because of the genes there are developing, but because of their proprietary gene delivery system. Companies such as Astra Zeneca, Merck, and Genentech have programs working with GNPX.
Inclusion in the Russell 3000 Index has increased Genprex’s visibility among institutional investors, money managers, and index funds. On February 5, 2021 Blackrock, Inc. increased its holdings in GNPX to 4.9% of the outstanding shares (marketbeat.com).
GNPXs lead product candidate is REQORSA (Tusc2 gene)
REQORSA™ immunogene therapy for non-small cell lung cancer (NSCLC), uses the company’s unique, proprietary ONCOPREX® nanoparticle delivery system which delivers cancer-fighting genes by encapsulating them into nanoscale hollow spheres called nanoparticles, which are then administered intravenously and taken up by tumor cells where they express proteins that are missing or found in low quantities.
In a recent development announced April 12th, Genprex collaborators reported positive preclinical data for REQORSA™
Rodney Varner, President and Chief Executive Officer of Genprex said. “We know that many patients inevitably develop resistance to immune checkpoint blockade therapy or EGFR-TKI therapy. These data show that REQORSA in combination with immunotherapies and targeted therapies may provide enhanced efficacy in NSCLC that has become resistant to these regimens, offering hope to a large patient population who currently has limited treatment options.”
Diabetes gene therapy, GPX-002 (Recent news April 20th, 2021)
Genprex to Receive Inaugural “License of the Year” Award from University of Pittsburgh Innovation Institute in Recognition of Advances Made with Gene Therapy Program in Diabetes
Groundbreaking, potentially curative gene therapy shown to transform alpha cells in the pancreas into functional beta-like cells is potentially applicable to both Type 1 and Type 2 diabetes
The company has signed a licensing agreement with the University of Pittsburgh for a diabetes gene therapy that could have the potential to cure Type 1 and Type 2 diabetes. The gene therapy, developed at the Rangos Research Center at UPMC Children’s Hospital of Pittsburgh, works by reprogramming beta cells in the pancreas to restore their function, allowing them to replenish insulin levels.
Trading 50% off its February high
High insider and institutional ownership
Jan-26-21 National Securities Buy $7.00/share target.
Stay tuned for our full report on GNPX with more information on their pipeline.
Together we’re strong,
The Traders News Group
Do we disclose any information to outside parties?
What information do we collect?
We collect information from you when you subscribe to our newsletter or fill out a form on one of our social platforms. This includes your email address and or mobile phone number.
When registering on our site, as appropriate, you may be asked to enter your: e-mail address and or mobile number.
What do we use your information for?
When we collect your email or mobile number it is used for one purpose to send you the information you requested about small cap stocks. Please read our disclaimer carefully before viewing our emails.
Your information, whether public or private, will not be sold, exchanged, transferred, or given to any other company for any reason whatsoever, other than for the express purpose of delivering the information on small cap stocks that you requested.
We send periodic emails
The email address you provide may be used to send you information, the small cap stock reports you requested, respond to inquiries, and/or other requests or questions.
How do we protect your information?
We implement a variety of security measures to maintain the safety of your personal information when you enter, submit, your email address. We use secure third parties to send email and sms messages to you.
Because we value your privacy we have taken the necessary precautions to be in compliance with the California Online Privacy Protection Act.
Traders News Source is a wholly owned subsidiary of Traders News Source LLC, herein referred to as TNS LLC.
Our reports/releases are a commercial advertisement and are for general information purposes ONLY. We are engaged in the business of marketing and advertising companies for monetary compensation. Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. The disclaimer is to be read and fully understood before using our services, joining our site or our email/blog list as well as any social networking platforms we may use.
Please Note: TNS LLC and its employees are not a registered investment advisor, Broker Dealer or a member of any association for other research providers in any jurisdiction whatsoever.